Purchase this article with an account.
P. A. Netland, S. R. Sarkisian, Jr., E. M. Kanner, H. Du; Consecutive Case Series of the Ex-PRESS Miniature Glaucoma Device Implanted Under a Scleral Flap. Invest. Ophthalmol. Vis. Sci. 2007;48(13):819.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Our purpose was to evaluate the clinical outcomes of the Ex-PRESS miniature glaucoma device placed under a partial-thickness scleral flap.
This was a retrospective, non-comparative case series. Patients with glaucoma not controlled with maximal medical therapy were treated with the Ex-PRESS implant (Optonol Ltd, Neve Ilan, Israel) under a scleral flap. Success was defined as intraocular pressure (IOP) between 5 and 21 mmHg with or without additional medication, and without further glaucoma surgery.
In this series, 300 eyes were consecutively treated with mean follow-up period of 17 months (range 3 to 36 months). The mean ± SD pre-operative IOP was 25.5 ± 10.3 mmHg, which was reduced to 14.7 ± 7.1 mmHg at 6 months (P < 0.001), 15.2 ± 7.9 mmHg at 9 months (P < 0.001), and 15.2 ± 7.9 at 1 year (P < 0.001) postoperatively. The number of glaucoma medications was significantly reduced during the postoperative period. The success rate was 89.0 % at 6 months, 87.3% at 9 months, and 84.9% at 1 year postoperatively. No erosion of the conjunctiva over the device occurred in this series. Five patients (1.7%) developed obstruction of the lumen of the Ex-PRESS implant, which was successfully treated with the Nd:YAG laser.
The Ex-PRESS miniature glaucoma device implanted under a scleral flap was safe and effective. Blockage of the lumen of the device in a small proportion of patients was treated with the Nd:YAG laser.
This PDF is available to Subscribers Only